In Simple Terms
PacBio and Verily are creating a secure digital space where researchers can study genetic information alongside people’s health records. They hope this will make it easier to research diseases and develop AI tools using richer information. The project is still being developed, and no results or wider rollout plans have been announced.
A multiyear partnership between PacBio and Verily Health aims to address a growing challenge in medical research: genetic information can reveal fine details about the body, but it becomes more useful when researchers can study it alongside related health information. The companies plan to connect long-read DNA sequencing with real-world health records, then organize and analyze the combined data on a digital platform for research and AI applications.
The announcement does not mean a new diagnostic tool is available or that the partnership has already produced a specific medical discovery. It describes a project to build a workflow that makes it easier to collect different kinds of biological and clinical data and use them more broadly. That distinction matters: understanding how a genome relates to a person’s health usually requires bringing together many kinds of information, managing access to it, and preparing it for analysis.
What Long Reads Can Reveal
PacBio’s HiFi technology reads long stretches of genetic material. Longer reads can help researchers identify some genetic changes and patterns that are difficult to detect when short fragments must be pieced together. They can offer a clearer picture of how different parts of the genome are arranged and related.
This approach can detect structural variants, which are changes involving the arrangement or size of sections of genetic material. It can also identify methylation patterns—chemical marks associated with DNA—and read full-length RNA molecules. These details give researchers more to examine in a sample than short sections of genetic code alone.
But broad genetic data cannot, by itself, explain how a person’s genes relate to their health or medical history. Genetic information and clinical records are different kinds of data, and collecting them may require separate tools and processes. The partnership is therefore focused on connecting the steps for generating genetic data with the tools to manage it and compare it with clinical information—not on developing a new sequencing device, according to the companies.
From Data Platform to Research Environment
At the center of the plan is Verily Pre, Verily’s platform for managing health data and using it in research and analysis. Under the agreement, PacBio’s sequencing workflows will be connected to the platform. Verily will also prepare its research Workbench environment to bring together HiFi genomic data and real-world clinical information, and to organize and analyze them.
The work involves more than storing files in one place. Organizations that handle health data need governance rules for managing and using the information, along with tools that make it searchable and analyzable in a well-controlled environment. Verily says its platform includes governance and modeling capabilities, as well as secure research tools. Its technologies are also designed to help health organizations work with protected health information.
The companies also say they will use a trusted, agent-based environment within Verily Pre to train AI models and run them for inference. Training is the process through which a model learns from data; inference is when a trained model processes new inputs and produces outputs. The announcement does not identify specific models or clinical applications, so it should not be taken as a launch announcement for a system ready to make treatment decisions.
Why Combine Genomic and Clinical Data?
Genetic data can describe inherited characteristics, while clinical information provides context about a person’s health as it appears in real life. When researchers can access both within an appropriate framework, they can study how genomic findings relate to recorded illnesses and healthcare. But combining data does not, on its own, guarantee sound conclusions. Careful scientific analysis, research design, and validation remain essential.
The partnership aims to support larger studies at research institutions, biotechnology and pharmaceutical companies, clinical centers, and programs studying genes across populations. Connecting the technical workflows could reduce the need to build separate systems for every project and help participating organizations work with larger, more complex sets of long-read data. The announcement offered no evidence yet to show whether this will lead to faster results or particular discoveries.
Verily executives cited neuroscience, oncology, rare diseases, and other fields with significant unmet medical needs as potential areas of interest. The focus reflects the growing use of genomic data in research, but it does not mean the partnership is centered on a single disease or has a treatment ready. Its stated goals concern the data infrastructure and tools researchers may use; any medical benefit will depend on the studies conducted in the future.
An Existing Starting Point—and Clear Limits
PacBio says its whole-genome sequencing workflows are already running within Verily Pre. That gives the proposed expansion a technical starting point, rather than requiring the companies to build the connection between their systems from scratch. They plan to extend the integration to longer-read and more complex programs as the partnership develops, but have not published a timeline.
Important details remain undisclosed. The companies have not revealed financial terms, participating customers, or when broader access might become available. They also have not specified the size of the data sets to be assembled or whether particular research projects will be first in line. The announcement is best understood as an agreement to develop technical integration and expand research capabilities—not as proof that a comprehensive platform or new service is already available to all institutions.
The partnership also highlights that using AI in medical research begins well before a model is built. Data must first be collected, organized, and linked in ways that support analysis, with safeguards in place for managing it. In this project, PacBio aims to contribute long-read sequencing data, while Verily provides an environment for managing and analyzing health information. The ultimate impact will depend on data quality, how the data are used, and what future studies find.
The Bottom Line
PacBio and Verily’s plan brings together long-read genetic sequencing—which can reveal details such as structural variants, methylation patterns, and RNA molecules—with a platform for managing and researching health data. The goal is to make it easier to create data sets that combine genomic and clinical information, and to support their use in research and in training and running AI models. But the effort is still being developed and expanded: the announcement reports no medical results and gives no details about customers, funding, or a timeline. What the partnership ultimately contributes will become clearer as research projects use the integrated system.